Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IMNN
IMNN | US
2.96
USD0.04
1.37%
IMNN | US
About IMNN
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
13/04/2026
Close
2.96
Open
3.00
High
3.04
Low
2.90
Imunon Inc. a clinical stage biotechnology company engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The Company's lead clinical programs comprise IMNN-001 a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma. It also has two platform technologies such as TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies; and PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The company was formerly known as Celsion Corporation and changed its name to Imunon Inc. in September 2022. Imunon Inc. was founded in 1982 and is based in Lawrenceville New Jersey.
View LessIMNN | US
Risk
51.3
Sharpe
-0.33
Luna's Score
42/100
Recommendation
Sell
Luna says (IMNN | US)
What's Working
Low Debt to Asset (< 0.2)
What's not Working
Price Below SMA10D
High Short-term Volatility
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
59.7%1 month
51.3%3 months
50.6%6 months
59.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.79
Debt to equity
0.37
Debt to assets
0.14
Ent. to EBITDA
0.91
Ent. to rev.
4.00
PEG
-
Other Fundamentals
EBITDA
-19.62M
MarketCap
42.63M
MarketCap(USD)
42.63M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-143.19
Short ratio
1.64
Short perc.
3.01
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.62
Range1M
0.72
Range3M
1.37
Volumes: Market Activity
Rel. volume
0.08
Price X volume
50.40K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.91 | - | Expensive |
| Ent. to Revenue | 4.00 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.79 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 50.63 | - | Lower Risk |
| Debt to Equity | 0.37 | -1.23 | Expensive |
| Debt to Assets | 0.14 | 0.25 | Cheaper |
| Market Cap | 42.63M | - | Emerging |
